you can go to the gynae and do a smear test or PAP test. If you have genital warts it's the bulk likely the type that causes cancer, but that may be impeded by doing a smear test every 6 months. If you're lucky and are clear you could take the anti-HPV vaccine ie Silgard or Gardera to alleviate the chances of getting it.



If you do have HPV always inform your partners and use a condom to avoid infecting anybody else.

There is no FDA DNA HPV test that will diagnosis male. A doctor can check to observe if you have visible genital warts with a vinegar solution and a magnification of your genital area.



Visible genital warts are usually low risk HPV types but 20 to 50% of the populations with genital warts also carry a co-infection of high risk HPV types.



If you partner was diagnosed with a high risk HPV type then you the bulk probably have high risk HPV types. Some men whose partners have high risk HPV type develop minute flat warts but the bulk men carry the virus with no visual signs.



Is there an HPV test for men?



There is currently no FDA-approved test to detect HPV in men. That is because an effective, reliable technique to collect a sample of male genital skin cells, which would enable detection of HPV, has yet to be developed. However, the Centers for Disease Control and Prevention advises men that they don’t need to be worried about the lack of an HPV test for them. The agency states that "there is no clear health benefit to knowing if men have this virus, since HPV is unlikely to influence their health and cannot be treated. For the bulk men, there will be no need to treat HPV, even if treatment were available, since it usually goes away on its own."



http://www.thehpvtest.com/HPV-for-men-FAQ.html





Genital warts

Condylomata bearing HPV-6 or -11 have identical clinical

manifestations and histology [2]. Recent studies have featured that about

100% of GWs are caused by either HPV-6 or -11 but that 20–50% of

lesions also contain co-infections with HR HPV types [3] and [4]. GWs

do not usually result in main morbidity or mortality, but cause

significant psychological morbidity and very substantial healthcare

costs. Occasionally GWs persist for long times of time and, rarely,

such long-standing lesions may progress to malignancy. GWs are highly

infectious, with a transmission rate of about 65% within sexual

partnerships from an infected to a prone sexual partner, and an

incubation period of between 3 weeks and 8 months, with the majority

developing warts at around 2–3 months [3]. Once GWs have developed,

they may express minimal alteration over time, become more numerous or

larger, or regress spontaneously. The bulk of placebo-controlled

GW therapy trials express low rates of regression (around 5% complete

clearance) in the short term, although in one study over 16 weeks 20%

of women and 5% of men using placebo completely cleared their warts,

and 38% of women and 22% of men using placebo cleared over 50% of

their baseline warts [3]. Regressing warts contain significantly more

CD4 positive T cells, both within the stroma underlying the lesions

and the condylomata themselves, and greater expression of activation

markers [3]. There is no report of the rate of spontaneous regression

that may eventuate in the longer term. Following GW clearance with

therapy, recurrence is average and is often seen within 3 months in 25%

of cases, although rates of up to 67% have been noticed [3]. In

clinical practice recurrences are often seen at sites of previous

lesions, and in these cases HPV infection in stem cells or

slow-turnover cells at the site of previous clearance has persisted

and then reactivated. The proportion of HPV-6/11 infections that are

either completely cleared or persist in a latent form after clinical

resolution is unknown, and, indeed, animal models suggest that both

outcomes can eventuate [3].

http://redigitaleditions.com/ActiveMagazine/getBook.asp?Path=ELS/2006/08/01&BookCollection=ELS&ReaderStyle=Gray